ABIOMED INC Form 8-K January 23, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report: January 19, 2012

(Date of earliest event reported)

## ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware 04-2743260

(State or other Jurisdiction	(IRS Employer
of Incorporation)	Identification Number) -20584
(Commission	
File Number)	
22 Cherry Hill Drive	
Danvers, MA 01923	
(Address of Principal Executive Offices, including Zip Code)	
(978) 646-1400	
(Registrant s Telephone Number, including Area Code)	
Not Applicable	
(Former Name or Former Address, if Changed Since Last Report)	
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:	
" Written communications pursuant to Rule 425 under the Securit	ies Act (17 CFR 230.425)
" Soliciting material pursuant to Rule 14a-12 under the Exchange	Act (17 CFR 240.14a-12)
" Pre-commencement communications pursuant to Rule 14d-2(b)	under the Exchange Act (17 CFR 240.14d-2(b))
" Pre-commencement communications pursuant to Rule 13e-4(c)	under the Exchange Act (17 CFR 240.13e-4(c)

#### Item 5.02 Departure of Directors or Principal Officers; Election of Directors or Appointment of Principal Officers.

On January 19, 2012, Dr. Eric A. Rose, a member of our Board of Directors, resigned as a director, effective immediately. We expect to enter into a consulting arrangement with Dr. Rose.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Abiomed, Inc.

By: /s/ Robert L. Bowen Robert L. Bowen Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

Date: January 23, 2012